-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cetuximab Biosimilar in Penile Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Biosimilar in Penile Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab Biosimilar in Penile Cancer Drug Details: Cetuximab biosimilar (CDP-1)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-0057 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-0057 in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-0057 in Epithelial Ovarian Cancer Drug Details: EP-0057 (NLG-207, CRLX-101)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Romosozumab in Osteogenesis Imperfecta
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Romosozumab in Osteogenesis Imperfecta report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Romosozumab in Osteogenesis Imperfecta Drug Details: Romosozumab (Evenity) is a humanized...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-0057 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-0057 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-0057 in Small-Cell Lung Cancer Drug Details: EP-0057 (NLG-207, CRLX-101)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-0057 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-0057 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-0057 in Transitional Cell Carcinoma (Urothelial Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-0057 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-0057 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-0057 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olokizumab in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olokizumab in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olokizumab in Rheumatoid Arthritis Drug Details: Olokizumab (Artlegia) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapirolizumab Pegol in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapirolizumab Pegol in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapirolizumab Pegol in Systemic Lupus Erythematosus Drug Details: Dapirolizumab pegol...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NLG-207 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Small-Cell Lung Cancer Drug Details: NLG-207 (CRLX-101) is under...